Qualified for CNS drug delivery

Management & Team


MANAGEMENT Dr. Heiko Manninga

Dr. Heiko Manninga is Managing Director and Chief Scientific Officer (CSO) of NEUWAY Pharma where he oversees the preclinical evaluation and further development of NEUWAY's Drug Delivery Technology. In only a year under his leadership, NEUWAY has built up the company and initiated several preclinical projects. Dr. Manninga also established a collaboration with a major pharma-ceutical partner and acquired additional public funding to support the further research program of NEUWAY Pharma. Dr. Manninga studied chemistry in G├Âttingen, and received his PhD in 2005 based on work at Max Planck Institute of Biophysical Chemistry in the lab of Dr. Thomas Tuschl, a pioneer in the field of ribonucleic acid interference (RNAi). After his post-doctoral studies, Heiko switched to the field of drug delivery as project director of Virus-Like Particles (VLP) Technology at the Life Science Inkubator (LSI) in Bonn. After his successful tenure at the LSI, Heiko served as interim manager during the spinout and funding process of the then-new company called NEUWAY Pharma and raised 6.725 million Euro from private and public investors during series A financing.


MANAGEMENT Dr. Rudi Scherhag

Dr. Rudi Scherhag is Managing Director and Chief Operating Officer (COO) of NEUWAY Pharma GmbH with responsibility for Administration, Finance & Controlling, Clinical Development, Regulatory Affairs and Business Development. Prior to joining NEUWAY in July 2015, he spent 5 years at ImClone Systems International, where he was instrumental for setting up ImClone┬┤s new international clinical development organization, initially as Head of Project Management and from 2010 as Managing Director. From 2001 to 2008 Rudi worked at Heidelberg Pharma as Head of Project Management & Business Development, CBO and member of the Board. Here he managed oncological projects and was responsible to form R&D partnerships. Rudi spent ~15 years with Boehringer Mannheim in product and project management with increasing responsibilities. As Global Project Leader for Epoetin beta he managed all life cycle activities (line extensions, new product forms) that formed the basis for this compound to become a block buster with peak sales of several billions USD. Rudi started his professional career in 1982 at Merckle as manager scientific affairs responsible for scientific advice for a wide range of pharmaceutical products and clinical indications.
Rudi has a Diploma and a PhD in Science of Nutrition from the University of Bonn, Germany.